Emideltide (DSIP)
Also known as: DSIP, Delta sleep-inducing peptide
Overview
Emideltide is the International Nonproprietary Name (INN) that appears in U.S. regulatory discussions for DSIP (delta sleep-inducing peptide), a short peptide historically investigated for sleep and stress-related effects. DSIP has been marketed widely online despite limited modern clinical evidence and an unclear mechanism of action. In practice, most products are sold as ‘DSIP,’ but advisory committee agendas and legal analyses often use the INN ‘Emideltide.’ For clinicians and patients, the naming matters because a regulatory docket may list Emideltide even if the marketplace talks about DSIP. In the U.S., Emideltide/DSIP is not an FDA-approved drug. If it were ever considered for compounding eligibility under Section 503A, the FDA would still weigh whether the substance can be adequately characterized, whether there are safety concerns (including immunogenicity and impurities), and whether any evidence supports the specific uses being proposed.
Mechanism of Action
DSIP/Emideltide has been reported to affect sleep architecture and neuroendocrine signaling in some experimental settings, but a definitive receptor target and reproducible human pharmacology have not been established.
Potential Benefits
- Research-stage only; no FDA-approved indications.
Research Dosage Notes
The following reflects doses used in published research studies. This is not medical advice.
No established dosing. Online dosing regimens are not evidence-based; discuss any use with a licensed clinician.
Routes of Administration
Not established
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Reconstitution
Need exact syringe measurements?
Amino Acid Sequence
Not yet characterized
Side Effects & Safety
- Human safety data are limited; potential risks include contamination/impurities from non-pharmaceutical sources and unknown long-term effects.
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy/breastfeeding (unknown safety)
Active cancer or history of hormone-sensitive malignancy (risk unknown)
Drug Interactions
- Unknown; insufficient human data
FDA Safety Information
Not FDA-approved. Compounding status is subject to FDA policy and advisory committee review; quality and sterility are key risks.
Pharmacokinetics
| Half-Life | Unknown |
|---|---|
| Storage | Store per supplier/manufacturer guidance; protect from heat and light. |
Synergistic Compounds
The following compounds have been studied alongside Emideltide (DSIP) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.